There Is A Reason Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Undemanding

Simply Wall StNov 12 17:40 ET

Ma Yinglong Report for the Third Quarter of 2024

SZSIOct 25 12:00 ET · Announcements

Mayinglong Pharmaceutical Group (600993.SH): The net income in the first three quarters was 0.458 billion yuan, a year-on-year increase of 9.35%.

Gelonghui October 25th | Mayinglong Pharmaceutical Group (600993.SH) released the third quarter report of 2024, with the company's revenue for the first three quarters reaching 2.792 billion yuan, a year-on-year increase of 14.13%; net income attributable to shareholders of the listed company was 0.458 billion yuan, a year-on-year increase of 9.35%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.449 billion yuan, a year-on-year increase of 24.62%; basic earnings per share was 1.06 yuan.

Gelonghui FinanceOct 25 04:19 ET

Mayinglong Pharmaceutical Group (SHSE:600993) Seems To Use Debt Rather Sparingly

Simply Wall StOct 24 19:03 ET

Mayinglong Pharmaceutical Group (SHSE:600993) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years

Simply Wall StOct 6 20:40 ET

Calculating The Fair Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Simply Wall StSep 18 21:36 ET